ReviewOncotarget2017
Concomitant
Review in Oncotarget, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 38 citations in OpenAlex.
- Review
- Rare sequential EGFR and ALK mutations in non-small cell lung cancer: A case report and literature review.Oncology letters · 2025Article
- Therapeutic strategies to overcomeFrontiers in oncology · 2024Article
- Concomitant EGFR Mutations and ALK Rearrangements in Lung Adenocarcinoma Treated With Osimertinib.Cureus · 2023Article
- Case report: ConcomitantFrontiers in pharmacology · 2023Article
- Coexistence of anaplastic lymphoma kinase rearrangement in lung adenocarcinoma harbouring epidermal growth factor receptor mutation: A single-center study.World journal of clinical cases · 2022Article
- Molecular Epidemiology of the Main Druggable Genetic Alterations in Non-Small Cell Lung Cancer.International journal of molecular sciences · 2021Review
- Integration of whole-exome and anchored PCR-based next generation sequencing significantly increases detection of actionable alterations in precision oncology.Translational oncology · 2021Article
- How should molecular findings be integrated in the classification for lung cancer?Translational lung cancer research · 2020Review
- Current Strategies for Treating NSCLC: From Biological Mechanisms to Clinical Treatment.Cancers · 2020Review
- Concomitant EGFR mutation and ALK rearrangement in multifocal lung adenocarcinoma: a case report.Diagnostic pathology · 2020Article
- Actionable Mutation Profiles of Non-Small Cell Lung Cancer patients from Vietnamese population.Scientific reports · 2020Article
- Concomitant Pathogenic Mutations and Fusions of Driver Oncogenes in Tumors.Frontiers in oncology · 2020Review
- The expression of circulating miR-504 in plasma is associated with EGFR mutation status in non-small-cell lung carcinoma patients.Cellular and molecular life sciences : CMLS · 2019Article
- Protein expression of close homologue of L1 (CHL1) is a marker for overall survival in non-small cell lung cancer (NSCLC).Journal of cancer research and clinical oncology · 2019Article
- Review
- Clinical Management of Non-Small Cell Lung Cancer with Concomitant EGFR Mutations and ALK Rearrangements: Efficacy of EGFR Tyrosine Kinase Inhibitors and Crizotinib.Targeted oncology · 2019Article
- Anaplastic Lymphoma Kinase (ALK)-positive Tumors: Clinical, Radiographic and Molecular Profiles, and Uncommon Sites of Metastases in Patients With Lung Adenocarcinoma.American journal of clinical oncology · 2019Article
- Concurrent Driver Gene Mutations as Negative Predictive Factors in Epidermal Growth Factor Receptor-Positive Non-Small Cell Lung Cancer.EBioMedicine · 2019Article
- Co-alteration of EGFR mutation and ALK rearrangement in non-small cell lung cancer: Case series.Medicine · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The discovery of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.